164 related articles for article (PubMed ID: 16818655)
1. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Inoue S; Mai A; Dyer MJ; Cohen GM
Cancer Res; 2006 Jul; 66(13):6785-92. PubMed ID: 16818655
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
Inoue S; MacFarlane M; Harper N; Wheat LM; Dyer MJ; Cohen GM
Cell Death Differ; 2004 Dec; 11 Suppl 2():S193-206. PubMed ID: 15608694
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.
Inoue S; Harper N; Walewska R; Dyer MJ; Cohen GM
Mol Cancer Ther; 2009 Nov; 8(11):3088-97. PubMed ID: 19887558
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.
MacFarlane M; Inoue S; Kohlhaas SL; Majid A; Harper N; Kennedy DB; Dyer MJ; Cohen GM
Cell Death Differ; 2005 Jul; 12(7):773-82. PubMed ID: 15861184
[TBL] [Abstract][Full Text] [Related]
5. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Earel JK; VanOosten RL; Griffith TS
Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression.
VanOosten RL; Moore JM; Karacay B; Griffith TS
Cancer Biol Ther; 2005 Oct; 4(10):1104-12. PubMed ID: 16096370
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
[TBL] [Abstract][Full Text] [Related]
9. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D.
Olsson A; Diaz T; Aguilar-Santelises M; Osterborg A; Celsing F; Jondal M; Osorio LM
Leukemia; 2001 Dec; 15(12):1868-77. PubMed ID: 11753607
[TBL] [Abstract][Full Text] [Related]
10. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
12. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
Rosato RR; Almenara JA; Dai Y; Grant S
Mol Cancer Ther; 2003 Dec; 2(12):1273-84. PubMed ID: 14707268
[TBL] [Abstract][Full Text] [Related]
14. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.
Schüler S; Fritsche P; Diersch S; Arlt A; Schmid RM; Saur D; Schneider G
Mol Cancer; 2010 Apr; 9():80. PubMed ID: 20398369
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.
Morales JC; Ruiz-Magaña MJ; Carranza D; Ortiz-Ferrón G; Ruiz-Ruiz C
Cancer Lett; 2010 Nov; 297(1):91-100. PubMed ID: 20580868
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.
Neuzil J; Swettenham E; Gellert N
Biochem Biophys Res Commun; 2004 Jan; 314(1):186-91. PubMed ID: 14715264
[TBL] [Abstract][Full Text] [Related]
19. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors: double edge sword for TRAIL cancer therapy?
Fulda S; Debatin KM
Cancer Biol Ther; 2005 Oct; 4(10):1113-5. PubMed ID: 16222120
[No Abstract] [Full Text] [Related]
[Next] [New Search]
